Rosiglitazone

• UNSPSC Description:

  Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].

• Target Antigen:

  Apoptosis; Autophagy; Ferroptosis; PPAR; TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Rosiglitazone.html

• Solubility:

  DMSO : 175 mg/mL (ultrasonic)|Ethanol : 2 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O

• Molecular Weight:

  357.43

• References & Citations:

  [1]Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.|[2]Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.|[3]Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70.|[4]Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30.|[5]Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220.|[6]Haoshen Feng, et al. Rosiglitazone ameliorated airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα. Int Immunopharmacol. 2021 Aug;97:107809. |[7]Zehua Wang, et al. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. Cancer Chemother Pharmacol. 2020 Feb;85(2):273-284. Acta Pharmacol Sin. 2023 May 24.|Adipocyte. 2021 Dec;10(1):646-657.|Adv Sci (Weinh). 2023 Jul 10;e2301088.|Am J Physiol Endocrinol Metab. 2024 Apr 3.|Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.|Antioxidants (Basel). 2024 Nov 24.|Aquaculture. 2024 Jan 15, 578, 740081.|Biochem Biophys Res Commun. 2020 Mar 26;524(1):70-76.|Biochem Biophys Res Commun. 2024 Nov 26.|Biochemistry (Moscow). 2021 May;86(5):568-576.|Biochim Biophys Acta Mol Cell Biol Lipids . 2020 Aug;1865(8):158711.|Biomed Pharmacother. 2020 Sep;129:110356.|Biomed Pharmacother. October 2022, 113653.|Biomedicines. 2021, 9(6), 677.|Bioorg Chem. 7 October 2022, 106191.|Bioorgan Med Chem. 15 February 2022, 116615.|Br J Pharmacol. 2020 May;177(10):2286-2302.|Cancer Cell Int. 2023 Aug 11;23(1):164.|Cancer Cell. 2024 May 13;42(5):869-884.e9.|Cancer Res. 2022 Apr 15;82(8):1503-1517.|Carcinogenesis. 2023 Mar 31;bgad015.|Cell Commun Signal. 2023 Sep 30;21(1):268.|Cell Death Differ. 2022 Nov 3.|Cell Death Dis. 2023 Apr 6;14(4):246.|Cell Death Dis. 2023 Dec 8;14(12):810.|Cell Death Dis. 2024 Sep 29;15(9):695.|Cell Death Dis.2024 May 21;15(5):350.|Cell Death Discov. 2022 Apr 30;8(1):236.|Cell Metab. 2021 Mar 2;33(3):581-597.e9.|Cell Metab. 2023 Dec 5;35(12):2165-2182.e7.|Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2.|Cell Mol Biol Lett. 2022 Feb 2;27(1):11.|Cell Prolif. 2023 Jun 15;e13520.|Cell Signal. 2022 Mar 6;110299.|Cells. 2022, 11(1), 86.|Chem Eng J. 2023 Aug 6, 145212.|Chinese Pharmacological Bulletin. 2017, 33(4): 517-521. |Circulation. 2022 Nov 30.|CNS Neurosci Ther. 2024 Nov;30(11):e70081.|Commun Biol. 2024 Apr 9;7(1):429.|Drug Dev Res. 2023 Apr 13.|Ecotoxicol Environ Saf. 2022 Jun 15;238:113611.|Endocr J. 2021 Oct 29.|Environ Int. 2023 Nov 25, 108354.|Eur J Med Chem. 2021 Aug 25;225:113807.|Eur J Med Chem. 5 February 2022, 114061.|Eur J Pharmacol. 2019 Jan 15;843:134-144.|Eur J Pharmacol. 2020 Sep 5;882:173300.|Eur J Pharmacol. 2022 Jul 31;175175.|Eur J Pharmacol. 2023 Oct 12:176113.|Food Funct. 2019 Dec 11;10(12):7983-7994.|Food Science and Human Wellness. 2023 Nov;12(6);2061-2072.|Free Radic Biol Med. 2018 Aug 21;126:259-268. |Front Cell Dev Biol. 2020 Jul 29;8:703.|Front Mol Neurosci. 2017 Sep 14;10:293.|Front Pharmacol. 2022 Jun 27;13:919202.|Front Physiol. 2019 Mar 1;10:165.|Front Vet Sci. 2023 Nov 17:10:1277586.|hLife. 2024 Mar 2.|Immunol Invest. 2021 Apr 8;1-18.|Inflamm Res. 2024 Aug 7.|Int Immunopharmacol. 2021 Jan;90:107150.|iScience. 10 October 2022, 105319.|iScience. 2023 Feb 28;26(4):106289.|J Biol Chem. 2024 Sep 12:107765.|J Cardiovasc Transl Res. 2024 Jul 9.|J Cell Mol Med. 2019 Oct;23(10):7029-7042. |J Cell Physiol. 2019 Nov;234(11):20694-20703. |J Ethnopharmacol. 2023 Dec 6:117550.|J Exp Clin Cancer Res. 2024 Dec 19;43(1):324.|J Exp Med. 2022 May 2;219(5):e20211906.|J Physiol Biochem. 2022 May;78(2):377-388.|J Therm Biol. 2024 Jul 2:123:103906.|J Zhejiang Univ Sci B. 2020 Dec; 21(12): 990–998.|Kidney Blood Press Res. 2021 Jul 28;1-12.|Life Sci. 2021 Jan 5;119013.|Mol Med. 2024 Nov 20;30(1):223.|Mol Metab. 2024 Oct 29:102053.|Molecules. 2024 Oct 15;29(20):4881.|Nat Commun. 2023 Jun 2;14(1):3208.|Nat Commun. 2023 May 15;14(1):2779.|Ocul Surf. 2024 Oct 10:S1542-0124(24)00108-3.|Oxid Med Cell Longev. 2021 Oct 14;2021:5527137.|Patent. US20180263995A1.|Pharmacol Res. 2020 Mar;153:104679.|Phytother Res. 2022 Nov 3.|PPAR Res. 2023 Nov 8:2023:6422804.|PPAR Res. 28 Sept 2022.|PPAR Res. 2019 Jul 1;2019:2715176. |Preprints. 2024 Aug 23.|Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 25;110758.|Redox Biol. 2023 Jun.|Ren Fail. 2022 Dec;44(1):2056-2065.|Reprod Domest Anim. 2023 Sep 15.|Research Square Print. 2022 Aug.|Sci Rep. 2024 Apr 30;14(1):9960.|Sci Total Environ. 2023 May 16;888:164073.|Sci Total Environ. 27 October 2022, 159755.|Stem Cell Res Ther. 2024 May 1;15(1):127.|Stem Cells Dev. 2022 Sep 21.|Theranostics. 2022 Jan 24;12(4):1904-1920.|Theranostics. 2022 Nov 7;12(18):7699-7716.|Front Mol Biosci. 2022 Feb 4;8:766887.|Pharmaceuticals. 2022, 15(9), 1055.|Research Square Preprint. 2024 Feb 7.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  122320-73-4